Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Data Published in the Lancet Show Fampridine-SR Improved Walking Ability in People with Multiple Sclerosis
March 20th, 2009
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced the publication of Phase 3 clinical trial data on Fampridine-SR in multiple sclerosis (MS) in the February 28 issue of The Lancet, one of the world’s leading medical journals. The trial, which included 301 participants at 33 leading MS centers in the U.S. and Canada, demonstrated that a significantly greater proportion of people with MS taking Fampridine-SR had a consistent improvement in walking speed compared to those receiving placebo (35 percent vs. 8 percent; p < 0.0001). Additional study assessments validated the clinical meaningfulness of improvements in walking speed, which was measured by the Timed 25-Foot Walk....
Source: Health Business Week (2009-03-20)
|
